The American Heart Association's Scientific Statement acknowledges that GLP-1-RAs have the potential to be effective in treating obesity, especially in patients with cardiovascular risk factors [97]
As a result, Medicaid coverage of GLP-1 drugs for obesity treatment is optional for states, while coverage for other indications (diabetes, cardiovascular disease, and sleep apnea) is required
Written reviews 0 Customers who bought this product also bought: 16 other products in the same category: 0.10 0.10 0.10 0.10 0.10 0.10
The genetic test reveals predispositions in peptide pathways, not pharmacogenomic responses or guarantees of exact medication efficacy
How PlexusDx Supports a More Personalized Approach PlexusDx recognizes that optimal peptide therapy selection depends on understanding both clinical mechanisms and individual genetic predispositions
Temperature Ideal : -20C (standard lab freezer)